All time high quarter for sales revenues, ending at MNOK 151.1, 11.4% above
fourth quarter last year (MNOK 135.6). Full year sales ended at MNOK 562.6, 6.9%
above last year (MNOK 526.4). 

Currency neutral sales of own products was up 9.7% for the quarter and 3.9% for
the full year. 

Recurring sales remained high at 71.5% (71.3%) for the quarter and 73.7% (69.3%)
for the year. 

AMERICAS delivered a strong quarter with 29.7% currency neutral growth. EMEA
showed strong performance with currency neutral growth of 10.9%. APAC was down
24.4% for the quarter. 

Operating profit (EBIT) for the quarter ended at MNOK 25.8 giving a 17.1% EBIT
margin (MNOK 22.3, a 16.4% margin). For the full year, EBIT was at MNOK 131,1
(MNOK 131.4) giving a 23.3% EBIT margin (25.0%).
 
Third-party distributor sales in Scandinavia increased 10.4% for the quarter and
13.1% for the year. 

In December, Medistim launched its new MiraQ INTUI software platform for Cardiac
surgery. 

For vascular surgery, Medistim launched a multicenter study of TTFM and HFUS
imaging as completion control in peripheral bypass. 

Solid cash position at quarter end with MNOK 179.2 and no interest-bearing debt.
The Board of Directors suggests a dividend of NOK 6.00 per share (NOK 4.5),
total MNOK 109.8 (MNOK 82.4).